Key result
Narrative review outlines available anticoagulants in Australia, detailing their relative strengths, weaknesses, and local landscape.
This narrative review provides an overview of the available anticoagulants, their strengths and weaknesses, and the current landscape of anticoagulation therapy in Australia.
Answers are grounded in this paper and cite their sources.
May inform Australian anticoagulation choices; extends prior reviews but leaves open the need for prospective local validation.
Anticoagulant therapy is prescribed for many clinical indications, including treatment and prevention of venous thromboembolism (VTE), such as deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as stroke prophylaxis in atrial fibrillation (AF) and to reduce the risk of prosthetic heart valve thrombosis and thromboembolism. In this narrative review, we briefly outline the anticoagulants available in Australia, their relative strengths and weaknesses, and the ever-changing local landscape with regards to anticoagulation therapy.
No takes yet. Share an insight, caveat, or question.
Favaloro et al. (2018) conducted a review in Venous thromboembolism, atrial fibrillation, and prosthetic heart valve thrombosis. Anticoagulant therapy was evaluated. This narrative review outlines the available anticoagulants in Australia, their relative strengths and weaknesses, and the local landscape regarding anticoagulation therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: